Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

Table 3 Comparison of grade 1-2 adverse reactions, n (%)

Adverse reaction	Control (n = 54)	Observation (n = 50)	χ2	P value
Leukopenia	22 (40.74)	20 (40.00)	0.005	0.938
Neutropenia	13 (24.07)	19 (38.00)	2.363	0.124
Lymphopenia	28 (51.85)	29 (58.00)	0.396	0.529
Thrombocytopenia	29 (53.70)	25 (50.00)	0.142	0.705
Hemoglobin reduction	23 (42.59)	22 (44.00)	0.020	0.885
Gastrointestinal reaction	20 (37.04)	17 (34.00)	0.104	0.746
Abnormal liver function	9 (16.67)	8 (16.00)	0.008	0.927
Pneumonia	4 (7.41)	3 (6.00)	0.011	0.916
Hypothyroidism	0 (0.00)	6 (12.00)	4.846	0.027